Human Reproduction, Vol. 14, No. 6, 1540-1545,
June 1999
© 1999 European Society of Human Reproduction and Embryology
Efficacy and safety of recombinant human follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for induction of spermatogenesis and fertility in gonadotrophin-deficient men
1 Andrology Unit, Royal Prince Alfred Hospital and Department of Medicine (DO2), University of Sydney, Sydney, NSW 2006 and 2 Royal Women's Hospital, Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Australia
In order to evaluate the efficacy and safety of recombinant human follicle stimulating hormone (r-hFSH) in combination with urinary human chorionic gonadotrophin (HCG) to induce spermatogenesis and fertility in gonadotrophin-deficient men, we conducted a prospective, open, non-comparative multicentre study in two Australian academic medical centres. Ten men with gonadotrophin deficiency requiring induction of spermatogenesis and fertility were treated with HCG for 36 months followed by the s.c. self-administration of injections of r-hFSH in combination with HCG for 18 months. Among the eight men who commenced r-hFSH treatment, seven demonstrated sperm output at a median of 6 months and five achieved the target sperm output of 1.5x106 per ml at a median of 9 months of FSH treatment. Mean testicular volume increased by 4.2 ml during FSH treatment. Three men produced pregnancies in their partners, two of which resulted in the birth of healthy babies and a third patient's partner had a miscarriage. We conclude that r-hFSH is well tolerated and effective in inducing testis growth, spermatogenesis and fertility in gonadotrophin-deficient men. The efficacy of r-hFSH seems comparable with urinary FSH at restoring normal fertility in gonadotrophin-deficient men.
Key words: gonadotrophin deficiency/HCG/recombinant FSH/spermatogenesis/testis
3 To whom correspondence should be addressed at: Department of Medicine (DO2), University of Sydney, Sydney NSW 2006, Australia
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
W. C. Hembree, P. Cohen-Kettenis, H. A. Delemarre-van de Waal, L. J. Gooren, W. J. Meyer III, N. P. Spack, V. Tangpricha, and V. M. Montori Endocrine Treatment of Transsexual Persons:An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3132 - 3154. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Y. Liu, H. W. G. Baker, V. Jayadev, M. Zacharin, A. J. Conway, and D. J. Handelsman Induction of Spermatogenesis and Fertility during Gonadotropin Treatment of Gonadotropin-Deficient Infertile Men: Predictors of Fertility Outcome J. Clin. Endocrinol. Metab., March 1, 2009; 94(3): 801 - 808. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Cailleux-Bounacer, Y. Reznik, B. Cauliez, J. F. Menard, C. Duparc, and J. M. Kuhn Evaluation of endocrine testing of Leydig cell function using extractive and recombinant human chorionic gonadotropin and different doses of recombinant human LH in normal men Eur. J. Endocrinol., August 1, 2008; 159(2): 171 - 178. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.A. Sinisi, D. Esposito, L. Maione, M.C. Quinto, D. Visconti, A. De Bellis, A. Bellastella, G. Conzo, and G. Bellastella Seminal anti-Mullerian hormone level is a marker of spermatogenic response during long-term gonadotropin therapy in male hypogonadotropic hypogonadism Hum. Reprod., May 1, 2008; 23(5): 1029 - 1034. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Coviello, A. M. Matsumoto, W. J. Bremner, K. L. Herbst, J. K. Amory, B. D. Anawalt, P. R. Sutton, W. W. Wright, T. R. Brown, X. Yan, et al. Low-Dose Human Chorionic Gonadotropin Maintains Intratesticular Testosterone in Normal Men with Testosterone-Induced Gonadotropin Suppression J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2595 - 2602. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Allan, A. Garcia, J. Spaliviero, F.-P. Zhang, M. Jimenez, I. Huhtaniemi, and D. J. Handelsman Complete Sertoli Cell Proliferation Induced by Follicle-Stimulating Hormone (FSH) Independently of Luteinizing Hormone Activity: Evidence from Genetic Models of Isolated FSH Action Endocrinology, April 1, 2004; 145(4): 1587 - 1593. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-M. G. Bouloux, E. Nieschlag, H. G. Burger, N. E. Skakkebaek, F. C.W. Wu, D. J. Handelsman, G. H.W. Baker, R. Ochsenkuehn, A. Syska, R. I. Mclachlan, et al. Induction of Spermatogenesis by Recombinant Follicle-Stimulating Hormone (Puregon) in Hypogonadotropic Azoospermic Men Who Failed to Respond to Human Chorionic Gonadotropin Alone J Androl, July 1, 2003; 24(4): 604 - 611. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ramaswamy, G. R. Marshall, C. R. Pohl, R. L. Friedman, and T. M. Plant Inhibitory and Stimulatory Regulation of Testicular Inhibin B Secretion by Luteinizing Hormone and Follicle-Stimulating Hormone, Respectively, in the Rhesus Monkey (Macaca mulatta) Endocrinology, April 1, 2003; 144(4): 1175 - 1185. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Y. Liu, V. J. Gebski, L. Turner, A. J. Conway, S. M. Wishart, and D. J. Handelsman Predicting pregnancy and spermatogenesis by survival analysis during gonadotrophin treatment of gonadotrophin-deficient infertile men Hum. Reprod., March 1, 2002; 17(3): 625 - 633. [Abstract] [Full Text] [PDF] |
||||




